🌟 Today, Frederik Barkhof is participating in the Symposium on the Global Consortium Approach to Alzheimer's Research, organised by the Alzheimer's Disease Data Initiative at #AAIC26, where he will share some AMYPAD insights!

🧠 Great to see the AMYPAD dataset continuing to advance #Alzheimers research! New in JAMA: a global meta-analysis pooling data from 53 studies "𝗪𝗵𝗮𝘁 𝗖𝗲𝗻𝘁𝗶𝗹𝗼𝗶𝗱 𝗰𝘂𝘁𝗼𝗳𝗳 𝘀𝗵𝗼𝘂𝗹𝗱 𝗱𝗲𝗳𝗶𝗻𝗲 𝗮𝗻 𝗮𝗺𝘆𝗹𝗼𝗶𝗱-𝗽𝗼𝘀𝗶𝘁𝗶𝘃𝗲 𝗣𝗘𝗧 𝘀𝗰𝗮𝗻?" 👇 jamanetwork.com/journals/jam...

🧠 Day 2 at #AAIC26 is officially underway! We are delighted to be part of this year's conference and to present our latest research through a series of posters from the AMYPAD project. 🌟 We are looking forward to an inspiring week of science, collaboration and meaningful discussions!

📩 The latest AMYPAD newsletter is here! Our newest edition is packed with updates from across the AMYPAD & Euro-PAD communities, highlighting exciting developments as we continue advancing Alzheimer's disease research. 📖 Read the newsletter here: mailchi.mp/557e200f0bce... @ihieurope.bsky.social

📢 New AMYPAD datasets now available for the global research community! We are pleased to announce the release of the updated raw and harmonised datasets from the AMYPAD Prognostic and Natural History Study (PNHS)! 👉 amypad.eu/news/recent-...

🌟 Glad to see more publications coming out using AMYPAD data. Read this paper investigating the associations of AD CSF biomarkers with early longitudinal amyloid deposition on positron emission. Congrats to Marianna Rizzo and all authors! @ihieurope.bsky.social journals.sagepub.com/doi/10.1177/...

Sage Journals: Discover world-class research

Subscription and open access journals from Sage, the world's leading independent academic publisher.

journals.sagepub.com

📢 New AMYPAD paper published in Alzheimer's & Dementia, analysing cross-sectional MRI and amyloid-β (Aβ) positron emission tomography (PET) data from 1323 AMYPAD participants. 👏 Congratulations to @lpieperhoff.bsky.social and all authors! @ihieurope.bsky.social ➡️ doi.org/10.1002/alz....

Cortical gray–white matter contrast alterations precede amyloid‐β positivity and macrostructural changes in older adults without dementia

INTRODUCTION Early Alzheimer's disease (AD) involves subtle cortical changes that may precede atrophy. Magnetic resonance imaging (MRI) microstructural markers may detect earlier pathology than clas...

doi.org

Grateful to have had the chance to present my work at the European Prevention of Alzheimer’s Disease symposium in Genova, Italy. #EUROPAD Many thanks to the organisers for the invitation @imi-amypad.bsky.social @biofinder.bsky.social #neuroimaging #brain #microstructure #alzheimersdisease #neuro

Please find our latest publication in Alzheimer's & Dementia: doi.org/10.1002/alz.... We find cortical gray-white matter tissue contrast to be a particularly early emerging MRI marker of Alzheimer's pathology, using the preclinical @imi-amypad.bsky.social Prognostic & Natural History Study!

Cortical gray–white matter contrast alterations precede amyloid‐β positivity and macrostructural changes in older adults without dementia

INTRODUCTION Early Alzheimer's disease (AD) involves subtle cortical changes that may precede atrophy. Magnetic resonance imaging (MRI) microstructural markers may detect earlier pathology than clas...

doi.org

📢 New paper "Self-reported sleep quality and longitudinal amyloid burden in clinically unimpaired adults from the AMYPAD PNHS study" has recently been accepted for publication in Alzheimer’s Research & Therapy. 👉 Read the paper here: link.springer.com/article/10.1... @ihieurope.bsky.social

Self-reported sleep quality and longitudinal amyloid burden in clinically unimpaired adults from the AMYPAD PNHS study - Alzheimer's Research & Therapy

Alzheimer's Research & Therapy - Poor self-reported sleep quality is associated with cognitive impairment. Alzheimer’s disease (AD) patients present sleep disruptions decades before...

link.springer.com

🗞️ Read the February IHI newsletter: link.europa.eu/HfTKq7 🤝 Our director on what makes a good public-private partnership 🚀 An interview with a young researcher on how working in our @imi-amypad.bsky.social project shaped her career 👋 New projects Cities@Heart & PROBE #HorizonEU #health #research

♀️ Today is the #InternationalDayofWomenandGirlsinScience! 🧠 Meet Ariane Bollack, a former PhD student from the AMYPAD project who's now working in industry. We asked her how the PPP shaped her career & what advice she has for young researchers 👉 link.europa.eu/K6GPPp #WomenInScience #WomenInSTEM

🎓 Meet Alba Martos Sánchez. She is a full-time PhD student at @barcelonabeta.bsky.social, doing some research in the early-stages of #Alzheimer’s disease. 👉 Read more: amypad.eu/news/recent-...

🎉 Congratulations Dr. Sophie Mastenbroek on successfully defending her PhD cum laude yesterday in Amsterdam 🎓 🌟Wishing Sophie continued success in the exciting journey ahead! www.amsterdamumc.org/en/research/...

🎓 Meet Prithvi Arunachalam. He is a PhD candidate at Amsterdam UMC, where he contributes to research initiatives including AMYPAD and Euro-PAD. 👉 Read more: amypad.eu/news/recent-...

👉 NEW AMYPAD paper presenting the AMYPAD approach to address data acquisition, processing, interpretation and data sharing challenges! Congratulations to all authors👏 alz-journals.onlinelibrary.wiley.com/doi/10.1002/...

Implementing robust amyloid PET quantification in multi‐center studies: AMYPAD approach to address data acquisition, processing, interpretation and data sharing challenges

INTRODUCTION Amyloid-positron emission tomography (PET) is pivotal to Alzheimer's management, with the Centiloid standardizing measurements across tracers. AMYPAD trials (Diagnostic and Patient Mana...

alz-journals.onlinelibrary.wiley.com

Today, @ihieurope.bsky.social hosted a webinar on regulatory impact. On behalf of AMYPAD, Gill Farrar presented how we succeeded in the Biomarker Qualification Opinion application for our Centiloid work! #RegulatoryScience #HorizonEurope #ResearchImpact

🚨 Happening today! Join us at 14:00 for Regulatory impact: what it is & how to achieve it with your IHI project. Hear from EMA regulators & past projects about their experiences, advice & top tips for achieving maximum impact. Don't miss it! 👉 link.europa.eu/vGdQrY #RegulatoryScience #HorizonEurope

📣New paper out on the role of cerebral amyloid-β in cortical, allocortical and subcortical atrophy in (mostly) cognitively unimpaired individuals from the AMYPAD Prognostic and Natural History Study! Congratulations to all authors👏 www.sciencedirect.com/science/arti...

Amyloid PET predicts atrophy in older adults without dementia: Results from the AMYPAD Prognostic & Natural History study

The impact of amyloid-β (Aβ) accumulation on regional brain atrophy in preclinical Alzheimer’s disease (AD), and its interaction with risk factors lik…

sciencedirect.com

Interested to learn how to maximise your project’s regulatory impact? Register for this online event hosted by @ihieurope.bsky.social ⤵️ www.ihi.europa.eu/news-events/... Gill Farrar will highlight the regulatory value that our AMYPAD Biomarker Qualification Opinion brought to the amyloid PET field

Innovative Health Initiative@ihieurope.bsky.social · 9mo ago

🔬 Do you want to better understand what #RegulatoryImpact means & how to achieve it with your IMI or IHI project? 🚀 Join us on 10 Dec at 14:00 & find out! Hear from @ema.europa.eu regulators & past projects 👉 link.europa.eu/vGdQrY #IHITransformingHealth #HealthResearch #EUResearch #RegulatoryScience

📢 Check out this perspective review, highlighting the advancements brought by blood biomarkers in Alzheimer's disease🧠🩸 doi.org/10.1002/alz....

Complementary utility of plasma biomarkers and Aβ‐PET for diagnosis, risk‐stratification, and treatment monitoring in Alzheimer's disease

With the rapid development of blood biomarkers (BBMs) related to amyloid-β (Aβ) pathology in Alzheimer's disease (AD), the question arises whether these can replace the accepted reference standard, ...

doi.org

We were pleased to join an exciting symposium during #EANM25 last week in Barcelona focused on advancing early diagnosis with PET imaging and biomarkers. Lyduine Collij shared AMYPAD insights and spoke alongside Prof. Dr. Alexander Drzezga and Prof. dr. Silvia Morbelli. amypad.eu/news/recent-...

📢 NEW paper out in Alzheimer's & Dementia, using data from the AMYPAD Prognostic and Natural History Study! Congratulations to all authors 👏 alz-journals.onlinelibrary.wiley.com/doi/10.1002/...

Cortical thickness subtypes in cognitively unimpaired individuals: Differential network and transcriptomic vulnerability to cortical thinning

INTRODUCTION The emergence, stability, and contributing factors of Alzheimer's disease (AD) gray matter subtypes remain unclear. METHODS We analyzed data from 1323 individuals without a diagnosis ...

alz-journals.onlinelibrary.wiley.com

🚀 We’re pleased to announce the release of the latest edition of our newsletter, featuring the release of the AMYPAD raw dataset, highlights from the Euro-PAD symposium and new papers! 👉 Read the full newsletter here: mailchi.mp/e602ab237ff7...

📣NEW AMYPAD out! The genetic data harmonisation manuscript for the AMYPAD consortium is online in Alzheimer's & Dementia! Authors provide a detailed pipeline for genotype array data QC, imputation, harmonisation, and PRS computation⤵️ doi.org/10.1002/alz....

📣 #AAIC25 is around the corner! Whether you’ll be on-site in Toronto or joining online, don’t miss the AMYPAD presentations 👇 For more information about the conference, please visit: aaic.alz.org

📢 NEW AMYPAD paper out in European Journal of Neurology assessing the cost-utility of early versus no amyloid-PET in the diagnostic work-up of memory clinic patients after 6 months. @ihieurope.bsky.social Congratulations to all authors 👏 doi.org/10.1111/ene....

Utility, Costs and Cost‐Utility of Amyloid‐PET in the Diagnostic Process of Memory Clinic Patients: A Trial‐Based Economic Evaluation From AMYPAD‐DPMS

Background Amyloid positron emission tomography (PET) is instrumental in achieving an accurate diagnosis and may help to limit health-seeking behavior. Currently, amyloid-PET is not routinely used i...

doi.org

This past two days, we hosted the Euro-PAD symposium to discuss the latest advancements in neuroimaging and biomarkers for #Alzheimer’s disease, as well as to share updates from the Euro-PAD initiative over the past year. ⤵️ www.barcelonabeta.org/en/news/news...

📣Yesterday and today, the Euro-PAD community convened in Barcelona for a scientific symposium hosted by @barcelonabeta.bsky.social. 👉Almost 100 participants gathered to discuss the latest advancements in neuroimaging and biomarkers for Alzheimer’s disease! amypad.eu/news/recent-...

This morning, before the symposium, we held two parallel workshops, one led by #BBRC researchers focused on fluid biomarkers and the other led by @acealzheimercenter.com focused on clinical trials